Caseware UK (AP4) 2024.0.164 2024.0.164 2024-06-302024-06-30trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2023-07-01falseNo description of principal activity1616falsefalse 06756342 2023-07-01 2024-06-30 06756342 2022-07-01 2023-06-30 06756342 2024-06-30 06756342 2023-06-30 06756342 c:Director1 2023-07-01 2024-06-30 06756342 d:MotorVehicles 2023-07-01 2024-06-30 06756342 d:MotorVehicles 2024-06-30 06756342 d:MotorVehicles 2023-06-30 06756342 d:MotorVehicles d:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 06756342 d:FurnitureFittings 2023-07-01 2024-06-30 06756342 d:FurnitureFittings 2024-06-30 06756342 d:FurnitureFittings 2023-06-30 06756342 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 06756342 d:ComputerEquipment 2023-07-01 2024-06-30 06756342 d:ComputerEquipment 2024-06-30 06756342 d:ComputerEquipment 2023-06-30 06756342 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 06756342 d:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 06756342 d:CurrentFinancialInstruments 2024-06-30 06756342 d:CurrentFinancialInstruments 2023-06-30 06756342 d:CurrentFinancialInstruments d:WithinOneYear 2024-06-30 06756342 d:CurrentFinancialInstruments d:WithinOneYear 2023-06-30 06756342 d:ShareCapital 2024-06-30 06756342 d:ShareCapital 2023-06-30 06756342 d:RetainedEarningsAccumulatedLosses 2024-06-30 06756342 d:RetainedEarningsAccumulatedLosses 2023-06-30 06756342 c:FRS102 2023-07-01 2024-06-30 06756342 c:AuditExempt-NoAccountantsReport 2023-07-01 2024-06-30 06756342 c:FullAccounts 2023-07-01 2024-06-30 06756342 c:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 06756342 2 2023-07-01 2024-06-30 06756342 e:PoundSterling 2023-07-01 2024-06-30 iso4217:GBP xbrli:pure

Registered number: 06756342










BLACKWATER PHARMA LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 JUNE 2024

 
BLACKWATER PHARMA LIMITED
REGISTERED NUMBER:06756342

STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
3,081
6,423

  
3,081
6,423

Current assets
  

Stocks
  
65,856
-

Debtors: amounts falling due within one year
 5 
149,336
128,455

Cash at bank and in hand
  
265,526
348,874

  
480,718
477,329

Creditors: amounts falling due within one year
 6 
(281,127)
(406,734)

Net current assets
  
 
 
199,591
 
 
70,595

Total assets less current liabilities
  
202,672
77,018

  

Net assets
  
202,672
77,018


Capital and reserves
  

Called up share capital 
  
8
8

Profit and loss account
  
202,664
77,010

  
202,672
77,018


Page 1

 
BLACKWATER PHARMA LIMITED
REGISTERED NUMBER:06756342
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 30 JUNE 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Mr B Rafferty
Director

Date: 14 March 2025

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
BLACKWATER PHARMA LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

1.


General information

Blackwater Pharma Limited is a private company limited by shares and incorporated in England and Wales, registration number 06756342. The registered office is 8 The Courtyards, Wyncolls Road, Severalls Industrial Park, Colchester, Essex, CO4 9PE.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Page 3

 
BLACKWATER PHARMA LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

2.Accounting policies (continued)

 
2.4

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.


 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Motor vehicles
-
20%
Straight line
Fixtures and fittings
-
20%
Straight line
Computer equipment
-
25%
Straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.



Page 4

 
BLACKWATER PHARMA LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

2.Accounting policies (continued)

 
2.9

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

 
2.10

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 16 (2023 - 16).

Page 5

 
BLACKWATER PHARMA LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

4.


Tangible fixed asset





Motor vehicles
Fixtures and fittings
Computer equipment
Total

£
£
£
£



Cost or valuation


At 1 July 2023
5,500
69,449
20,414
95,363


Additions
-
-
2,436
2,436


Disposals
(5,500)
-
-
(5,500)



At 30 June 2024

-
69,449
22,850
92,299



Depreciation


At 1 July 2023
1,283
68,390
19,267
88,940


Charge for the year on owned assets
-
489
1,072
1,561


Disposals
(1,283)
-
-
(1,283)



At 30 June 2024

-
68,879
20,339
89,218



Net book value



At 30 June 2024
-
570
2,511
3,081



At 30 June 2023
4,217
1,059
1,147
6,423

Page 6

 
BLACKWATER PHARMA LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

5.


Debtors

2024
2023
£
£


Trade debtors
106,133
121,230

Called up share capital not paid
8
8

Prepayments and accrued income
2,650
399

Tax recoverable
40,545
6,818

149,336
128,455



6.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
150,941
321,564

Amounts owed to group undertakings
115,707
30,289

Corporation tax
5,501
47,473

Other taxation and social security
1,896
703

Employer pension
609
540

Accruals and deferred income
6,473
6,165

281,127
406,734


 
Page 7